MilliporeSigma’s Andrew Bulpin will serve as a panelist during a virtual conversation with distinguished scientists and academic experts from both sides of the Atlantic on what lies ahead as the Covid-19 pandemic stretches into 2021 and vaccination campaigns are underway.
Burlington, Massachusetts, January 27, 2021 — MilliporeSigma’s Andrew Bulpin will serve as a panelist during a virtual conversation with distinguished scientists and academic experts from both sides of the Atlantic on what lies ahead as the Covid-19 pandemic stretches into 2021 and vaccination campaigns are underway. The discussion is sponsored by the German-American Business Council of Boston, Inc. and the Consulate Generals of both the Federal Republic of Germany Boston and the Federal Republic of Germany San Francisco.
Bulpin leads MilliporeSigma’s global Process Solutions business unit, which provides products, services and expertise to help customers improve every step of their manufacturing process. MilliporeSigma develops the manufacturing templates and provides products now being used by some 50 customers working on Covid-19 vaccine candidates. Bulpin will discuss what he and his colleagues are doing to plan for the future and move forward from this crisis.
WHO: Andrew Bulpin, executive vice president of Process Solutions at MilliporeSigma.
Bulpin will join the following panellists:
· Johannes Ahrendts, head of strategy at GAVI, The Vaccine Alliance.
· Antony Blanc, chief business officer and chief commercial officer at CureVac.
· Melanie Ott, director of Gladstone Institute of Virology and professor, Department of Medicine, UC San Francisco.
Jan Hartmann, vice president and head of Medical Affairs, Clinical Development & Medical Safety, Haemonetics, and member of the GABC Board of Directors, will moderate the panel discussion.
WHAT: Talk exploring the challenges and opportunities involved fighting the Covid-19 pandemic. A Q&A session will take place during the event.
WHEN: Thursday, February 4, 2021 at 1 p.m. EST.
WHERE: Click here to register to attend. To join the webinar, click here. Webinar ID: 836 9123 1930
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 58,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €12.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
